![Richard Mulligan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 10 M $ in data 31/07/2026
Richard Charles Mulligan is the founder of Sarissa Capital Management LP, founded in 2013, where the title held was Senior Managing Director & Founding Partner from 2013 to 2016.
Current jobs include Vice Chairman at Kadmon Pharmaceuticals LLC since 2010, Vice Chairman at Sana Biotechnology, Inc. since 2018, Director-Harvard Gene Therapy Initiative at Harvard Medical School since 1996, Independent Director at International Flavors & Fragrances, Inc. starting in 2025, Member at US Food & Drug Administration, and Member-Supervisory Board at Biogen GmbH since 2009.
Former jobs include Vice Chairman at Enzon Pharmaceuticals, Inc. from 2011 to 2013, Director at Forest Laboratories, Inc., Director at ImClone LLC from 2006 to 2008, Independent Director at Biogen, Inc. from 2009 to 2023, Director at Genzyme Corp., Independent Director at Cellectis SA, Director at Biogen Idec New Ventures, Inc., Independent Director at Bausch Health Cos., Inc. from 2022 to 2026, Portfolio Manager at Icahn Capital LP from 2017 to 2018, Member at Whitehead Institute for Biomedical Research, Chief Scientific Officer at Somatix Therapy Corp., and Professor-Molecular Biology at Massachusetts Institute of Technology from 1991 to 1996.
Education includes undergraduate degree from Massachusetts Institute of Technology and doctorate from Stanford University School of Medicine.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 04/06/2026 | 2.698.121 ( 1,04% ) | 8 M $ | 31/07/2026 | |
| 18/05/2026 | 155.616 ( 0,04% ) | 1 M $ | 31/07/2026 | |
| 01/05/2026 | 1.712 ( 0% ) | 135 625 $ | 31/07/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| SANA BIOTECHNOLOGY, INC. | Direttore/Membro del Consiglio | 01/11/2018 |
| INTERNATIONAL FLAVORS & FRAGRANCES INC. | Direttore/Membro del Consiglio | 20/10/2025 |
Biogen GmbH
 Biogen GmbH Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures and supplies pharmaceutical products | Direttore/Membro del Consiglio | 01/01/2009 |
Kadmon Pharmaceuticals LLC
 Kadmon Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Direttore/Membro del Consiglio | 01/11/2010 |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/1996 |
US Food & Drug Administration
 US Food & Drug Administration General GovernmentGovernment Operates agencies to protect health and human services | Corporate Officer/Principal | - |
| Società | Posizione | Fine |
|---|---|---|
| BAUSCH HEALTH COMPANIES INC. | Direttore/Membro del Consiglio | 19/05/2026 |
| BIOGEN INC. | Direttore/Membro del Consiglio | 26/06/2023 |
Icahn Capital LP
 Icahn Capital LP Investment Trusts/Mutual FundsMiscellaneous Acts as Hedge Fund | Corporate Officer/Principal | 01/10/2018 |
| ░░░░░░░ ░░░░░░░ ░░░░░░░░░░ ░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 20 |
|---|---|
Enzon Pharmaceuticals, Inc.
 Enzon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops innovative therapeutics for cancer patients | Health Technology |
Forest Laboratories, Inc.
 Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and sells drug products | Health Technology |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology Develops novel therapeutic products and blood cell growth factors for the treatment of cancer | Health Technology |
International Flavors & Fragrances, Inc.
 International Flavors & Fragrances, Inc. Food: Specialty/CandyConsumer Non-Durables Manufactures food flavor compounds, pharmaceutical excipients, cosmetic active and natural health ingredients | Consumer Non-Durables |
Somatix Therapy Corp.
 Somatix Therapy Corp. BiotechnologyHealth Technology Provides biological products | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Icahn Capital LP
Icahn Capital LP Investment Trusts/Mutual FundsMiscellaneous Acts as Hedge Fund | Miscellaneous |
Sarissa Capital Management LP
 Sarissa Capital Management LP Investment ManagersFinance Sarissa seeks to achieve superior risk-adjusted returns by constructing a portfolio, primarily across healthcare and related sectors, where there is a significant discrepancy between market value and intrinsic value. They frequently use activism to close this discrepancy. The firm employs a fundamental, research-driven, value-oriented approach to identify potential investments. They conduct rigorous, fundamentals-based research. Sarissa is an activist firm and is included in SharkWatch50 as one of the 50 most prominent and impactful activist investors. | Finance |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Cellectis SA
 Cellectis SA Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops immunotherapies | Health Technology |
Whitehead Institute for Biomedical Research
 Whitehead Institute for Biomedical Research Miscellaneous Commercial ServicesCommercial Services Provides research and technology services | Commercial Services |
US Food & Drug Administration
US Food & Drug Administration General GovernmentGovernment Operates agencies to protect health and human services | Government |
Biogen Idec New Ventures, Inc.
 Biogen Idec New Ventures, Inc. Investment ManagersFinance Biogen Idec New Ventures' strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently. Their specific areas of interest are companies in Biogen Idec's current therapeutic areas of neurology, oncology and immunology/inflammation, but they also seek opportunities outside these areas that fit their strategies for longer-term growth. The firm invests at all stages of development; most of their investments are in early-stage companies. They also look for investment opportunities where they can leverage their parent's resources and scientific and development expertise to support these investments. | Finance |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biogen GmbH
Biogen GmbH Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures and supplies pharmaceutical products | Health Technology |
Bausch Health Cos., Inc.
 Bausch Health Cos., Inc. Pharmaceuticals: OtherHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
Kadmon Pharmaceuticals LLC
Kadmon Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Health Technology |
Stanford University School of Medicine
 Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sana Biotechnology, Inc.
 Sana Biotechnology, Inc. BiotechnologyHealth Technology Operates as a biotechnological company which creates and delivers engineered cells as medicine for patients | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
